Diabetes can bankrupt the USA by 2040. If this device works for wireless glucose monitoring, and can double as a transdermal drug delivery system, the company WILL be bought out by big pharma as soon as FDA and or EU approvals are applied for. My bet is on Novo Nordisk or J&J. Therefore they want to put out as much stock as possible, then drive up the price through successful clinicals and good data (let's hope for the best), before they sell it off for billions. I am buying more, but only at less than today's asking price.
I think we all agree on the "potential", but why does management keep financing and at horrendous terms? Something doesn't match. Management isn't being opportunistic in their financing, they are acting desperate at the shareholder's expense.